바이오의약품 시장 : 제품 유형, 기술, 투여 경로, 제형, 보존 조건, 치료 영역, 최종 사용자, 유통 채널, 환자층별 - 세계 시장 예측(2026-2032년)

The Biologics Market is projected to grow by USD 719.17 billion at a CAGR of 6.61% by 2032.

Biologics Executive Summary: Precision Therapies Drive the Next Era of Healthcare

Biologics are reshaping healthcare by translating advances in immunology, cell biology, recombinant DNA technology, and precision medicine into therapies that target disease mechanisms with high specificity. The biologics landscape includes monoclonal antibodies, recombinant proteins, vaccines, blood and plasma products, cell and gene therapies, antibody-drug conjugates, and biosimilars used across oncology, autoimmune disease, rare disease, infectious disease, metabolic disorders, and neurology.

Momentum is supported by sustained regulatory approvals, rising chronic disease burden, expanding biologics manufacturing capacity, and the increasing clinical value of targeted therapies. The U.S. FDA's Center for Drug Evaluation and Research approved 55 novel drugs in 2023, including biologic products, while biosimilar adoption continues to broaden following the first U.S. biosimilar approval in 2015 and more than 80 biosimilar approvals in Europe since 2006. For industry leaders, competitive advantage increasingly depends on clinical differentiation, scalable bioprocessing, supply chain resilience, regulatory excellence, and evidence generation across the product lifecycle.

Transformative Shifts in the Biologics Landscape

The biologics landscape is undergoing a structural shift from volume-led pharmaceutical models to science-led, outcome-oriented innovation. Monoclonal antibodies remain a core commercial engine, while bispecific antibodies, antibody-drug conjugates, mRNA platforms, cell therapies, and gene therapies are expanding the definition of biological medicines. This transition is increasing demand for specialized capabilities in cell line development, viral vector production, single-use bioprocessing, cold chain logistics, potency testing, and comparability analytics.

At the same time, biosimilars are changing access and pricing dynamics. Regulatory confidence in biosimilar comparability has strengthened in the United States, Europe, Japan, and several emerging markets, encouraging payer adoption and tender-based competition. The industry is also responding to policy pressure around affordability, including U.S. Medicare drug price negotiation under the Inflation Reduction Act and ongoing European initiatives to improve medicine access. These shifts are pushing manufacturers to balance innovation, cost efficiency, patient access, and lifecycle management with greater discipline.

Cumulative Impact of Artificial Intelligence on Biologics

Artificial intelligence is becoming a practical accelerator across biologics discovery, development, manufacturing, and commercialization. In discovery, AI-enabled protein modeling, antibody design, epitope prediction, and developability screening help reduce experimental burden and improve candidate selection. In clinical development, machine learning supports biomarker discovery, patient stratification, trial site selection, protocol optimization, pharmacovigilance signal detection, and real-world evidence analysis.

The cumulative impact of AI is strongest when data quality, governance, and regulatory traceability are embedded from the start. Biologics development generates complex datasets from omics, imaging, process analytics, bioassays, electronic health records, and manufacturing sensors. Organizations that connect these data streams can improve process control, reduce batch failure risk, support quality-by-design strategies, and accelerate regulatory responses. However, AI deployment must be validated, explainable, and aligned with evolving guidance from agencies such as the FDA, EMA, and ICH to ensure patient safety and compliance.

Key Regional Insights Across Global Biologics Markets

North America remains a leading biologics region due to deep biotech funding, advanced clinical trial infrastructure, strong intellectual property protection, and mature regulatory pathways for biologics and biosimilars. The United States anchors the region, supported by FDA review capacity, major biomanufacturing clusters, high specialty medicine utilization, and strong biomedical investment. Canada contributes through clinical research networks, biologics manufacturing investments, and public reimbursement frameworks that increasingly evaluate biosimilars for cost containment.

Europe combines scientific depth with a well-established biosimilar framework. The European Medicines Agency approved the first biosimilar in 2006, and European markets have accumulated extensive real-world experience with switching and tendering. Germany, France, Italy, Spain, and the United Kingdom remain important centers for biologics consumption, clinical research, and advanced therapy development, while European pharmaceutical policy is emphasizing access, supply security, and innovation competitiveness.

Asia-Pacific is advancing rapidly as China, Japan, South Korea, India, Australia, and ASEAN markets expand biologics development and manufacturing. China has accelerated biologics approvals and domestic innovation, India is a major biosimilar and vaccine manufacturing base, Japan maintains rigorous quality and reimbursement systems, and South Korea has built globally competitive biosimilar capabilities. Latin America is led by Brazil and Mexico, where biologics access is expanding through public health systems, private care growth, and local regulatory modernization. The Middle East, particularly GCC countries, is investing in specialty care infrastructure and national health transformation, while Africa is at an earlier stage but gaining attention for vaccine access, cold chain strengthening, regulatory capacity building, and local production initiatives supported by public health priorities.

Key Group Insights for Biologics Strategy

The G7 remains central to biologics innovation because the United States, Japan, Germany, France, the United Kingdom, Italy, and Canada combine advanced research ecosystems, reimbursement capacity, and mature regulatory systems. These markets shape clinical standards, pricing debates, pharmacovigilance expectations, biosimilar policies, and global launch sequencing for biologic therapies.

The European Union is a global reference point for biosimilar regulation, centralized marketing authorization, and health technology assessment coordination. Its policy direction increasingly connects medicine availability, manufacturing resilience, and competitiveness in life sciences. BRICS countries are becoming more influential as China, India, Brazil, Russia, and South Africa expand domestic manufacturing, biosimilar development, vaccine production, and public-sector procurement. China and India are especially important to cost-competitive biologics supply and clinical development scale, while Brazil and South Africa strengthen regional access priorities through public health systems.

ASEAN is emerging as a growth corridor as Indonesia, Thailand, Vietnam, Malaysia, Singapore, and the Philippines expand specialty care access and regulatory harmonization efforts. Singapore is a high-value biomanufacturing and regional headquarters hub, while larger ASEAN markets drive patient access needs across oncology, autoimmune disease, and diabetes care. GCC countries are investing in oncology, diabetes, immunology, and rare disease care through hospital modernization and national health transformation programs. NATO markets overlap significantly with North America and Europe, making them strategically important for supply security, regulatory alignment, emergency preparedness, and resilient pharmaceutical logistics.

Key Country Insights Shaping Biologics Growth

The United States is the most influential biologics market, driven by FDA approvals, high specialty drug use, advanced clinical research, and strong biotech capital formation. Biosimilar uptake has improved in therapeutic areas such as oncology and immunology, although adoption varies by reimbursement design, formulary management, and provider incentives. Canada is focused on access, cost containment, and biosimilar switching policies across provinces, while Mexico is expanding biologics demand through private healthcare, public procurement, and regulatory modernization.

Brazil leads Latin America in biologics consumption and local production ambitions, supported by a large public health system and technology transfer models. The United Kingdom remains a strong life sciences hub with NHS-led biosimilar adoption and advanced therapy initiatives. Germany combines high healthcare spending with strong biopharmaceutical manufacturing and early access pathways, while France emphasizes innovation, reimbursement evaluation, and domestic health sovereignty. Italy and Spain continue to expand biosimilar use through regional procurement and hospital-based prescribing. Russia maintains domestic production priorities and import substitution policies, although geopolitical and supply chain constraints affect international participation.

China has become a major biologics innovation and manufacturing market, supported by regulatory reforms, domestic antibody pipelines, and expanding oncology care. India is a global supplier of vaccines and biosimilars, with competitive manufacturing economics and rising domestic demand. Japan offers a high-quality regulatory environment and strong demand for oncology, immunology, and regenerative medicine. Australia contributes through clinical trials, reimbursement access, and biomedical research, while South Korea is recognized for large-scale biosimilar manufacturing, contract development capabilities, and global biologics exports.

Actionable Recommendations for Biologics Industry Leaders

Industry vendors should prioritize differentiated biologics pipelines supported by strong biomarker strategies, clinically meaningful endpoints, and early payer evidence. Organizations developing monoclonal antibodies, bispecifics, antibody-drug conjugates, cell therapies, gene therapies, vaccines, and biosimilars should build integrated plans that connect target validation, developability, manufacturing scalability, regulatory strategy, and market access from the earliest stages.

Manufacturers should invest in flexible bioprocessing, dual sourcing, raw material risk management, cold chain visibility, and digital quality systems to reduce supply disruptions. AI and automation should be deployed where they can be validated and measured, including process analytics, deviation detection, literature surveillance, clinical trial optimization, and pharmacovigilance workflows. Commercial teams should strengthen real-world evidence generation, physician education, patient support, and biosimilar confidence programs to improve adoption, adherence, and persistence.

Strategic partnerships with contract development and manufacturing organizations, academic centers, diagnostics specialists, healthcare systems, and regional distributors can accelerate geographic expansion. Companies should also monitor regulatory convergence, interchangeability policies, pharmacovigilance requirements, health technology assessment reforms, and drug pricing policies to align launch strategy with local evidence expectations and affordability priorities.

Research Methodology for Biologics Market Intelligence

This executive summary is developed using a structured secondary research approach focused on verified public sources and industry-standard evidence. Key inputs include regulatory agency publications from the FDA, EMA, Health Canada, Japan's PMDA, China's NMPA, and other national authorities; policy information from the World Health Organization, OECD, and national health ministries; clinical trial registries; peer-reviewed literature; pharmacovigilance resources; reimbursement documentation; and public biomanufacturing policy updates.

The methodology evaluates biologics through product class, therapeutic area, regulatory pathway, manufacturing model, regional demand indicators, reimbursement environment, and competitive intensity. Insights are triangulated across approval trends, biosimilar adoption evidence, biomanufacturing investments, clinical pipeline signals, public health priorities, and healthcare policy developments. Emphasis is placed on data-backed interpretation rather than unsupported forecasts, ensuring that the analysis remains credible for executives, investors, manufacturers, and market access leaders.

Conclusion: Biologics Leadership Requires Science, Scale, and Access

Biologics are at the center of pharmaceutical innovation, combining scientific precision with substantial clinical and strategic opportunity. The landscape is being reshaped by advanced modalities, biosimilar competition, AI-enabled development, regional manufacturing expansion, and stronger evidence requirements from regulators and payers.

Organizations that combine differentiated science with scalable manufacturing, trusted quality systems, resilient supply chains, and market-specific access strategies will be best positioned to lead. As healthcare systems pursue better outcomes and sustainable spending, biologics developers and manufacturers must prove value through clinical performance, affordability, regulatory confidence, and reliable global supply.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biologics Market, by Product Type

• 7.1. Blood Factor Products
• 7.2. Cell Therapies
  • 7.2.1. CAR-T Therapies
  • 7.2.2. Stem Cell Therapy
• 7.3. Gene Therapies
• 7.4. Monoclonal Antibodies
• 7.5. Recombinant Proteins
• 7.6. Vaccines

8. Biologics Market, by Technology

• 8.1. Cell Culture Technology
• 8.2. Gene Editing Technology
  • 8.2.1. CRISPR
  • 8.2.2. TALENs
  • 8.2.3. Zinc Finger Nucleases
• 8.3. Hybridoma Technology
• 8.4. Recombinant DNA Technology

9. Biologics Market, by Route Of Administration

• 9.1. Intramuscular
• 9.2. Intravenous
• 9.3. Subcutaneous

10. Biologics Market, by Presentation Format

• 10.1. Vials
• 10.2. Prefilled Syringes
• 10.3. Cartridges
• 10.4. Autoinjectors

11. Biologics Market, by Storage Condition

• 11.1. Refrigerated
• 11.2. Frozen
• 11.3. Room Temperature Stable

12. Biologics Market, by Therapeutic Area

• 12.1. Autoimmune
• 12.2. Cardiovascular Diseases
• 12.3. Infectious Diseases
• 12.4. Metabolic Disorders
• 12.5. Neurological Disorders
• 12.6. Oncology

13. Biologics Market, by End User

• 13.1. Clinics
• 13.2. Home Healthcare
• 13.3. Hospitals
• 13.4. Research Institutes

14. Biologics Market, by Distribution Channel

• 14.1. Hospital Pharmacy
• 14.2. Online Channel
• 14.3. Retail Pharmacy

15. Biologics Market, by Patient Population

• 15.1. Pediatric
• 15.2. Adult
• 15.3. Geriatric

16. Biologics Market, by Region

• 16.1. Asia-Pacific
• 16.2. North America
• 16.3. Latin America
• 16.4. Europe
• 16.5. Middle East
• 16.6. Africa

17. Biologics Market, by Group

• 17.1. ASEAN
• 17.2. GCC
• 17.3. European Union
• 17.4. BRICS
• 17.5. G7
• 17.6. NATO

18. Biologics Market, by Country

• 18.1. United States
• 18.2. Canada
• 18.3. Mexico
• 18.4. Brazil
• 18.5. United Kingdom
• 18.6. Germany
• 18.7. France
• 18.8. Russia
• 18.9. Italy
• 18.10. Spain
• 18.11. China
• 18.12. India
• 18.13. Japan
• 18.14. Australia
• 18.15. South Korea

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025

20. Company Profiles

• 20.1. AbbVie Inc.
• 20.2. Ajinomoto Bio-Pharma Services
• 20.3. Amgen Inc.
• 20.4. Amneal Pharmaceuticals, Inc.
• 20.5. AstraZeneca PLC
• 20.6. Aurobindo Pharma Limited
• 20.7. Avantor, Inc.
• 20.8. Baxter International Inc.
• 20.9. Bayer AG
• 20.10. Becton, Dickinson and Company
• 20.11. Biogen Inc.
• 20.12. BioNTech SE
• 20.13. Boehringer Ingelheim International GmbH
• 20.14. Bristol-Myers Squibb Company
• 20.15. Catalent Inc.
• 20.16. Celltrion Inc.
• 20.17. Chugai Pharmaceutical Co., Ltd.
• 20.18. Cipla Limited
• 20.19. CSL Limited
• 20.20. Danaher Corporation
• 20.21. Eli Lilly and Company
• 20.22. F. Hoffmann-La Roche AG
• 20.23. Gilead Sciences Inc.
• 20.24. GlaxoSmithKline plc
• 20.25. Johnson & Johnson Services Inc.
• 20.26. Lonza Group AG
• 20.27. Merck & Co. Inc.
• 20.28. Moderna Inc.
• 20.29. Novartis AG
• 20.30. Pfizer Inc.
• 20.31. Samsung Biologics Co. Ltd.
• 20.32. Sanofi SA
• 20.33. Takeda Pharmaceutical Company Limited